Summary
Signal counts
Assets tracked: 1
Watchlist assets: 1
Registry stop assets: 0
Sponsor overview
National Cancer Center, Korea
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT00506844
Assets
Linked programs
- Cetuximab, Irinotecan, Capecitabine: Watchlist Signal (2/5)